BCAX
Bicara Therapeutics Inc. Common StockNASDAQHealthcare$21.47+4.73%OpenMarket Cap: $1.18B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.95
P/S
0.00
EV/EBITDA
-7.15
DCF Value
$1.64
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-32.0%
ROIC
-38.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-37.4M | $-0.68 |
| FY 2025 | $0.00 | $-137.9M | $-2.52 |
| Q3 2025 | $0.00 | $-36.3M | $-0.67 |
| Q2 2025 | $0.00 | $-27.4M | $-0.50 |
Analyst Ratings
View AllGoldman SachsNeutral
2026-03-31Wells FargoEqual Weight
2026-03-31CitizensMarket Outperform
2026-03-31HC Wainwright & Co.Buy
2026-03-31WedbushOutperform
2026-03-31Trading Activity
Insider Trades
View AllRaben Davidofficer: Chief Medical Officer
SellThu Mar 26
Raben Davidofficer: Chief Medical Officer
SellThu Mar 26
Hyep Ivanofficer: Chief Financial Officer
SellTue Mar 24
Hyep Ivanofficer: Chief Financial Officer
SellTue Mar 24
Mazumdar Clairedirector, officer: Chief Executive Officer
SellFri Mar 20
Latest News
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.The Motley Fool · Thu Mar 26
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.77
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.